Anti Cancer Medicines
Showing 33–48 of 49 results
-
SYLVANT (siltuximab) for Injection, for Intravenous infusion Initial U.S. Approval: [yyyy]
Read more -
SYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998
Read more -
TABRECTA (capmatinib) tablets, for oral use Initial U.S. Approval: 2020
Read more -
TEGSEDI (inotersen) injection, for subcutaneous use. Initial U.S. Approval: 2018
Read more -
TEPEZZA (teprotumumab-trbw) for injection, for intravenous use Initial U.S. Approval: 2020
Read more -
TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use. Initial U.S. Approval: 2019
Read more -
TRODELVY (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020
Read more -
TUKYSA (tucatinib) tablets, for oral use Initial U.S. Approval: 2020
Read more -
UNITUXIN (dinutuximab) injection, for intravenous use Initial U.S. Approval: 2015
Read more -
VEGZELMA (bevacizumab-adcd) injection
Read more -
VISTOGARD (uridine triacetate) oral granules Initial U.S. Approval: 2015
Read more -
VITRAKVI (larotrectinib) oral solution Initial U.S. Approval: 2018
Read more -
VORAXAZE (glucarpidase) For Injection, for intravenous use. Initial U.S. Approval: 2012
Read more -
VOTRIENT (pazopanib) tablets. Initial U.S. Approval: 2009
Read more -
WELIREG (belzutifan) tablets
Read more -
XALKORI (crizotinib) capsules
Read more